Engineered for the biotherapeutic race
Our SCIENTIFIC INTELLIGENCE and research teams are industry experts, pioneers, and empowered freethinkers who are skilled at turning antibody research into clinical realities.
We deliver beyond full-scale antibody discovery and development services, driven by relentlessly robust:
- Outcomes, with diverse candidate pools and libraries
- Sequence and profile identification with a Function-First focus
- Unparalleled focus and identification of clinically relevant antibodies
- Platforms and technologies
- A whole new approach to AI for biotherapeutics with LENSai ™ Integrated Intelligence Technology
Accelerate antibody discovery breakthroughs with an expanded network of people, platforms and technologies.
Your ultimate source for protein production
Extensive catalog of antibodies and recombinant proteins, including organoid growth factors: IPA is exclusive producer of WNT Surrogate-Fc fusion protein that is cited in multiple peer review journals.
IPA custom rPEx® production: >8,000 batches of antigens, antibodies, bi- and multi-specific antibodies with >95% purity* — renowned for its flexibility, reliability and efficiency. Discover our excellence. Programs shipped in 8 weeks / 4 weeks for repeat batch production.
*Historical consolidated average
Lead the way with IPA.
We have the longest memory
Rabbit monoclonal antibodies with B Cell Select® with Function-First from IPA are unmatched for early identification of a high affinity, highly specific antibodies.
Bispecifics & IPA
Bring us your scaffold and we can do the rest. With years of experience using a variety of bi- and multi-specific modalities, IPA has end-to-end capabilities and throughput to ensure selection and development of the most relevant therapeutic candidates.
Wet lab + in silico
LENSai in silico applications for radically informed decisions are designed to lend great cost and time efficiencies, as part of the IPA antibody discovery portfolio of service.
1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118